Leesa Gentry - 03 Apr 2026 Form 4 Insider Report for RenovoRx, Inc. (RNXT)

Reporting relationship: Chief Clinical Officer
Issuer ticker: RNXT
Reported as of: 03 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Apr 2026, 20:00:03 UTC
Prior SEC filing: 03 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Leesa Gentry

Key filing fact

Leesa Gentry filed Form 4 for RenovoRx, Inc. (RNXT) on 07 Apr 2026.

Key facts

This page summarizes Leesa Gentry's Form 4 filing for RenovoRx, Inc. (RNXT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 07 Apr 2026, 20:00.

Change

Previous filing in this sequence was filed on 03 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002013097 Primary reporting owner

Gentry Leesa

Relationship: Chief Clinical Officer
Address: C/O RENOVORX, INC., 2570 W EL CAMINO REAL, SUITE 320, MOUNTAIN VIEW
Signature: /s/ Leesa Gentry
Signature date: 07 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RNXT transaction Derivative

Stock Option

Award

Transaction value
Shares: +128,550
Change %
Price: $0.000000^*
Shares after: 128,550
Date: 03 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 128,550
Exercise price: $0.9800
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On April 3, 2026, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 128,550 shares of the Issuer's common stock (66,954 shares of which are underlying incentive stock options and 61,596 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2026. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2030, and will expire on April 3, 2036.